Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease.

ABSTRACT:

Background

Sorafenib is the recommended treatment for advanced hepatocellular carcinoma (HCC), but transarterial chemoembolization (TACE) is performed in individual cases with limited extrahepatic spread. The aim of this study was to compare the outcome of patients with HCC and extrahepatic disease (EHD) treated with sorafenib and TACE.

Methods

A total of 172 patients with HCC and EHD treated with sorafenib (n = 98) or TACE (n = 74) at three German referral centers (Hannover, Mainz and Hamburg) were included in this study. In order to reduce selection bias, patients were matched for significant demographic differences using a propensity score analysis.

Results

Patients with liver cirrhosis, higher extrahepatic tumor burden and/or infiltration of adjacent

SUBMITTER: Kirstein MM 

PROVIDER: S-EPMC5833223 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature